Zhongsheng Pharmaceutical (002317): Continued innovation and transformation, influenza medicine will soon be launched

Core view: The company released the 2023 annual report and the 2024 quarterly report: achieved operating income of 2,611 billion yuan in 2023, -2.45% year on year; net profit to mother was 263 million yuan, -18.25% year on year, the main

廣發證券Apr 26 16:56

Zhongsheng Pharmaceutical (002317.SZ): Net profit of 51.9939 million yuan in the first quarter decreased 63.20% year over year

Gelonghui, April 22 | Zhongsheng Pharmaceutical (002317.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 641 million yuan, down 14.15% year on year; net profit attributable to shareholders of listed companies was 51.2939 million yuan, down 63.20% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 72.2269 million yuan, down 43.58% year on year; basic earnings per share were 0.06 yuan.

Gelonghui FinanceApr 22 21:30

Express News | Zhongsheng Pharmaceutical: Phase I clinical trial of RAY1225 injection, a holding subsidiary, obtained top-line analysis data results

BreakingsMar 25 18:46

Zhongsheng Pharmaceutical (002317.SZ): Actively exploring the layout of classic traditional Chinese medicine recipes and the development of in-hospital formulations

Gelonghui, March 14, 丨 Zhongsheng Pharmaceutical (002317.SZ) said at an investor relations event that it is actively exploring the layout of classic traditional Chinese medicine recipes and the development of in-hospital formulations. In line with the country's policy guidelines to encourage the inheritance, innovation and development of traditional Chinese medicine, and based on the company's therapeutic positioning and market resource advantages, the company actively uses external R&D resources to cooperate in the development of classic traditional Chinese medicine recipes and in-hospital formulations, and continues to broaden the traditional Chinese medicine product pipeline.

Gelonghui FinanceMar 14 19:14

A-share innovative pharmaceutical stocks collectively opened higher, and many stocks such as Zhaoyan New Pharmaceutical rose and stopped

Gelonghui, March 14 | Zhaoyan Pharmaceutical, Sailong Pharmaceutical, and Luoxin Pharmaceutical rose and stopped; Zhongsheng Pharmaceutical, Hengrui Pharmaceutical, and Hisco are close to rising or stopping. Eddy Pharmaceuticals, Betta Pharmaceuticals, Biotech, Junshi Biotech, and Colon Pharmaceuticals all strengthened collectively. According to the news, a document on the “Implementation Plan for Supporting the Development of Innovative Drugs in the Whole Chain (Draft for Comments)” was distributed online, which was interpreted by the market as a major benefit for the innovative drug industry.

Gelonghui FinanceMar 14 09:29

Zhongsheng Pharma's Chairman to Raise Stake in Company

Guangdong Zhongsheng Pharmaceutical's (SHE:002317) chairman and president, Chen Yonghong, plans to increase his holdings in the company, according to a March 8 filing published on the Shenzhen Stock E

MT NewswiresMar 11 18:27